Market Size

The back of the eye disorders market, valued at USD 17.06 billion in 2025, is projected to reach USD 18.28 billion in 2026 and USD 41.56 billion by 2035, representing a CAGR of 9.6% during the forecast period 2026 to 2035. Kindly note that implants and devices related to the back of the eye disorders market have been excluded from the scope of this report.

Global Back of the Eye Disorders Market Growth 2025 to 2035

See What’s in the Full Report – Request Your Complimentary Insights!

Market Report: Key Takeaways

Driven by rising ocular disease awareness programs and innovations in long-acting anti-VEGF agents, drug developers are capitalizing on the growing demand for early-stage detection and preventive care.
In terms of scale of operation, the commercial scale segment secures around 95% of the overall revenue share in 2026 due to the established product portfolio of players, wider market penetration, and significantly higher annual sales contribution from approved therapies.
In terms of sub-categories of type of molecule, biologics currently hold more than 90% of the market share, due to their superior compatibility to target wide range of biological pathways associated with back of the eye disorders.

Back of the Eye Disorders Market Share by Type of Molecule, 2026 and 2035

With respect to target indication, the diabetic macular edema market segment dominates (~40%) the current back of the eye disorders market size.
In terms of geographical regions, North America captures around 60% of the market value in the year 2026, due to strong public and private investments in this region, along with supportive regulations, and significant funding initiatives that propel regional growth.

Market Overview

The therapies for back of the eye disorders and novel drug delivery systems represent a critical component in modern ophthalmology, designed to treat vision-threatening conditions affecting the retina, macula, and vitreous. Prominent disorders in this category include age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME), and retinal vein occlusion.

By integrating advanced biologics, gene therapies, sustained-release platforms, and innovative drug delivery technologies, drug developers in the domain aim to overcome the formidable anatomical barriers of the posterior segment while improving therapeutic efficacy, durability, and patient outcomes.

Building on these advancements, the back of the eye disorders market continues to expand steadily. This growth is primarily driven by continuous innovations in anti-VEGF agents, bispecific antibodies, long-acting formulations, port delivery systems, and emerging gene and cell therapies that seek to reduce treatment frequency and enhance retinal protection. However, the field still encounters significant challenges in effective drug delivery across the blood-retinal barrier and management of the high treatment burden associated with frequent intravitreal injections.

Nevertheless, the rising global prevalence of diabetes and aging populations, coupled with growing investments in precision ophthalmology and next-generation delivery technologies, are fueling robust market growth.

Back of the Eye Disorders Market Drugs and Developers

Recent Developments

In April 2026, MeiraGTx acquired botaretigene sparoparvovec (bota-vec), an investigational AAV gene therapy for X-linked retinitis pigmentosa (XLRP) due to RPGR mutations, from Johnson & Johnson.
In March 2026, Sumitomo Pharma received FDA Orphan Drug Designation for its drug candidate DSP-3077, an investigational allogeneic iPSC-derived 3D retinal organoid for the treatment of retinitis pigmentosa.
In January 2026, DKSH Malaysia forged a strategic alliance with AbbVie to deliver commercial services for its premier ophthalmology portfolio across Malaysia’s pharmacy network. Building on prior collaborations with AbbVie in Vietnam and Thailand, this partnership bolsters AbbVie’s regional footprint and commercial prowess in Asia’s eye care sector.

Your Business is Unique – Why Shouldn’t Your Report Be?

Back of the Eye Disorders Market Trends

Biosimilars Market Expansion: FDA approvals of interchangeable biosimilars, such as Nufymco (ranibizumab) in 2026 has significantly lowered the costs for anti-VEGF therapies, broadening access for chronic back of the eye conditions. This counters high pricing challenges, fostering competition and adoption in price-sensitive markets.
Growing Emphasis on Sustained-Release Delivery Systems: Innovations in sustained-release implants and intravitreal devices, exemplified by Roche’s Susvimo, demonstrate sustained durability in neovascular age-related macular degeneration (nAMD), with approximately 95% of patients requiring no supplemental treatment prior to six-month refills.
Growth in Industry Engagement: Back of the eye domain has witnessed a surge in number of events, such as conferences, webinars and symposiums. In fact, players are proactively conducting and participating in events to discuss their research findings related to novel drug modalities being developed in the domain.
Rising Investment in Complement-Targeted and Cell / Gene Therapies: Several gene therapies targeting the complement system, such as CTx001 by Complement Therapeutics received FDA Fast Track Designation in early 2026 for geographic atrophy. This reflects accelerated development efforts to address the large unmet need in dry AMD, wherein options remain limited compared to wet AMD therapies.

Back of the Eye Disorders Market Company Competitiveness Analysis

Industry Experts on Back of the Eye Disorders Market

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

Former Chief Executive Officer, Small Company, Australia
Former President and Chief Executive Officer, Mid-sized Company, US
Former Senior Vice President, Small Company, US

In addition, the back of the eye disorders market report includes transcripts of the following third-party discussions:

Associate Professor & Senior Consultant, Mid-sized Organization, Italy
Assistant Professor, Very Large Organization, US
Postdoctoral Researcher, Very Large Organization, US

Artificial intelligence will mark a turning point in back of the eye disorders domain in the coming future. T. Y. Alvin Liu, assistant professor at Johns Hopkins University states, “I think we’re very fortunate that ophthalmology has been at the forefront of the AI revolution in medicine, and I see two major applications right now. The first one is clinical; the second one is more on the research side. On the clinical side, the most mature AI application in ophthalmology is the use of autonomous AI for the detection of diabetic retinopathy in the primary care setting.”

Market Drivers

Escalating Prevalence of Age-related and Diabetes-associated Retinal Disorders: The escalating diabetes epidemic, coupled with the growing aging population, is fundamentally expanding the pool of patients for back of the eye disorders, such as AMD and DR. In fact, as per a research article, approximately 200 million people worldwide are living with AMD, and this figure is projected to increase to nearly 300 million by 2040. This demographic shift has created sustained demand for therapeutic interventions, positioning drugs targeting the posterior segment as essential components of modern eye care.
Innovations in Long-Acting Anti-VEGF Agents and Novel Delivery Systems: Continuous advancements in drug formulations, such as extended duration of anti-VEGF therapies, sustained-release implants, and early gene therapy are reducing injection frequency, improving visual outcomes, and lowering treatment burden. Moreover, maturing pipelines and faster approvals are driving clinician adoption, fueling the overall market growth.
Improved Diagnostic Technologies and Heightened Disease Awareness Programs: Widespread adoption of high-resolution imaging tools like OCT and enhanced screening programs, supported by global awareness campaigns enable earlier detection of posterior segment pathologies. This drives timely treatment, increases treatable cases, and boosts long-term market momentum.

Pay Only for What You Need – The Best Way to Optimize

Market Segmentation Analysis

Clinical Pipeline Growth Driving the Back of the Eye Disorders Industry

According to back of the eye disorders market forecast, the commercial scale sub-segment dominates the market (95%), driven by the increased demand for commercialized drug therapies owing to their improved efficacy and safety profile.
Clinical stage drugs are likely to grow at a higher CAGR, showcasing substantial growth potential during the forecast period. This growth is due to the increasing approvals of novel back of the eye disorder related modalities and their ongoing exploration across diverse target indications. Examples of phase III drugs anticipating approval in the upcoming years include KSI-501 (Kodiak Sciences), OVX-001 (Ocuvex Therapeutics), ADX-2191 (Aldeyra Therapeutics), ONS-5010 (Outlook Therapeutics) and OTX-TKI (Ocular Therapeutix).

Back of the Eye Disorders Market Outlook by Scale of Operation, 2026 and 2035

Diabetic Macular Edema Therapeutics Lead the Back of the Eye Disorders Industry with Unparallel Demand

In 2026, diabetic macular edema sub-segment holds around 40% of the overall back of the eye disorders market share. This high share stems from the increasing global prevalence of diabetes, fueled by aging population, sedentary lifestyle, and poor dietary habits.
Some of the approved drugs for diabetic macular edema include Eylea®, Eylea HD®, Lumitin®, Lucentis® and Vabysmo. In addition to this, OCS-01, an investigational, preservative-free drug developed by Oculis for diabetic macular edema, is expected to advance towards approval pending successful Phase III clinical trial results.
It is important to highlight here that according to our market analysis, the uveitic macular edema sub-segment is likely to grow at a higher CAGR during the forecast period. Notably, the increasing incidence of non-infectious uveitis, expanding use of long-acting intravitreal implants and targeted biologic agents, coupled with significant unmet need and improving reimbursement landscape fuel this dominance.

Market Regional Insights

North America Dominates the Market

In 2035, North America’s back of the eye disorders market will likely dominate, capturing around 60% of the market share. Key factors that contribute to the region’s dominance in this industry include robust partnerships between academia and industry, cutting-edge manufacturing capabilities for potent compounds and comprehensive intellectual property activity.

Moreover, the growing mergers and acquisitions in back of the eye disorders domain is one of the primary reasons for the market growth in the region. For instance, Bausch + Lomb recently announced that one of the company’s affiliates acquired Whitecap Biosciences, a California based company developing two innovative investigational therapies. This strategic collaboration strengthens Bausch + Lomb’s clinical-stage pipeline in ophthalmology by adding potential new treatments for glaucoma and geographic atrophy, an advanced form of dry age-related macular degeneration.

Back of the Eye Disorder Related Drugs Adoption in the Asia-Pacific Region

Asia-Pacific is likely to observe considerable back of the eye disorders market growth of 11.9% in the forecast period. Notable examples of very large companies based in Asia-Pacific which are actively developing back of the eye disorders related drugs include Astellas Pharma and Otsuka Pharmaceutical. The detailed methodology across the global back of the eye disorders market and revenue generated across various segments is available in the full report.

Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed

Back of the Eye Disorders Market: Scope of the Report

Key Report Attributes	Details
Historical Trend	Since 2022
Forecast Period	Till 2035
Market Size 2026	USD 18.28 Billion
Market Size 2035	USD 41.56 Billion
CAGR (Till 2035)	9.6%
Key Players Profiled	AbbVie Astellas Pharma Bausch + Lomb Chiesi Genentech Novartis Otsuka Pharmaceutical Regeneron Pharmaceuticals Roche Sun Pharma (A complete list of companies captured is available in the report)
Segments Covered	Scale of Operation Type of Molecule Target Indication Geographical Regions
Excel Data Packs (Complimentary)	Market Landscape Company Competitiveness Analysis Market Forecast and Opportunity Analysis
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization

Market Segments

Based on the market research, we have segmented the Back of the Eye Disorders Market Report into scale of operation, type of molecule, target indication, and geographical regions.

By Scale of Operation

Clinical Scale
Commercial Scale

By Type of Molecule

Biologics
Small Molecules

By Target Indication

Diabetic Macular Edema
Neovascular (Wet) Age-Related Macular Degeneration
Diabetic Retinopathy
Glaucoma
Geographic Atrophy
Uveal Melanoma
Retinal Vein Occlusion
Uveitic Macular Edema
Choroidal Neovascularization
Biallelic RPE65 mutation-associated Retinal Dystrophy
Retinopathy of Prematurity
Leber's Hereditary Optic Neuropathy

By Geographical Regions

North America
- US
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
Middle East and North Africa
- Saudi Arabia
- Egypt
- Rest of Middle East and North Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America

+ 1. BACKGROUND

1.1. Context

1.2. Project Objectives

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.2.1. Market Landscape and Market Trends

2.2.2. Market Forecast and Opportunity Analysis

2.2.3. Comparative Analysis

2.3. Database Building

2.3.1. Data Collection

2.3.2. Data Validation

2.3.3. Data Analysis

2.4. Project Methodology

2.4.1. Secondary Research

2.4.1.1. Annual Reports

2.4.1.2. Academic Research Papers

2.4.1.3. Company Websites

2.4.1.4. Investor Presentations

2.4.1.5. Regulatory Filings

2.4.1.6. White Papers

2.4.1.7. Industry Publications

2.4.1.8. Conferences and Seminars

2.4.1.9. Government Portals

2.4.1.10. Media and Press Releases

2.4.1.11. Newsletters

2.4.1.12. Industry Databases

2.4.1.13. Roots Proprietary Databases

2.4.1.14. Paid Databases and Sources

2.4.1.15. Social Media Portals

2.4.1.16. Other Secondary Sources

2.4.2. Primary Research

2.4.2.1. Types of Primary Research

2.4.2.1.1. Qualitative Research

2.4.2.1.2. Quantitative Research

2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary Research

2.4.2.3.1. Interviews

2.4.2.3.2. Surveys

2.4.2.3.3. Focus Groups

2.4.2.3.4. Observational Research

2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research

2.4.2.4.1. Company Executives (CXOs)

2.4.2.4.2. Board of Directors

2.4.2.4.3. Company Presidents and Vice Presidents

2.4.2.4.4. Research and Development Heads

2.4.2.4.5. Technical Experts

2.4.2.4.6. Subject Matter Experts

2.4.2.4.7. Scientists

2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity

2.4.2.5.1. Research Ethics

2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

+ 3. MARKET DYNAMICS

3.1. Chapter Overview

3.2. Forecast Methodology

3.2.1. Top-down Approach

3.2.2. Bottom-up Approach

3.2.3. Hybrid Approach

3.3. Market Assessment Framework

3.3.1. Total Addressable Market (TAM)

3.3.2. Serviceable Addressable Market (SAM)

3.3.3. Serviceable Obtainable Market (SOM)

3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques

3.4.1. Qualitative Forecasting

3.4.2. Correlation

3.4.3. Regression

3.4.4. Extrapolation

3.4.5. Convergence

3.4.6. Sensitivity Analysis

3.4.7. Scenario Planning

3.4.8. Data Visualization

3.4.9. Time Series Analysis

3.4.10. Forecast Error Analysis

3.5. Key Considerations

3.5.1. Demographics

3.5.2. Government Regulations

3.5.3. Reimbursement Scenarios

3.5.4. Market Access

3.5.5. Supply Chain

3.5.6. Industry Consolidation

3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

+ 4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview

4.2. Market Dynamics

4.2.1. Time Period

4.2.1.1. Historical Trends

4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage

4.2.2.1. Major Currencies Affecting the Market

4.2.2.2. Factors Affecting Currency Fluctuations

4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate

4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market

4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession

4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation

4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates

4.2.6.1. Interest Rates and Their Impact on the Market

4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis

4.2.7.1. Type of Commodity

4.2.7.2. Origins and Destinations

4.2.7.3. Values and Weights

4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics

4.2.8.1. Import Scenario

4.2.8.2. Export Scenario

4.2.8.3. Trade Policies

4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers

4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis

4.2.9.1. Russian-Ukraine War

4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors

4.2.10.1. Global Economic Impact

4.2.10.2. Industry-specific Impact

4.2.10.3. Government Response and Stimulus Measures

4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators

4.2.11.1. Fiscal Policy

4.2.11.2. Consumer Spending

4.2.11.3. Gross Domestic Product (GDP)

4.2.11.4. Employment

4.2.11.5. Taxes

4.2.11.6. Stock Market Performance

4.2.11.7. Cross-Border Dynamics

4.3. Conclusion

+ 5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape

5.2. Executive Summary: Market Forecast and Opportunity Analysis

+ 6. INTRODUCTION

6.1. Overview of Back of the Eye Disorders

6.2. Back of the Eye Structure

6.3. Challenges Associated with Back of the Eye Drug Delivery

6.4. Back of the Eye Drug Delivery Routes

6.5. Prominent Back of the Eye Disorders

6.6. Factors Contributing to Back of the Eye Disorders

6.7. Sign and Symptoms of Back of the Eye Disorders

6.8. Treatment Approaches for Back of the Eye Disorders

6.9. Recent Trends in the Back of the Eye Disorders Domain

+ 7. BACK OF THE EYE DISORDERS MARKET: DRUGS AND DEVELOPERS LANDSCAPE

7.1. Methodology and Key Parameters

7.2. Back of the Eye Disorders Market: Drugs Landscape

7.2.1. Analysis by Stage of Development

7.2.2. Analysis by Type of Molecule

7.2.3. Analysis by Mechanism of Action

7.2.4. Analysis by Dosing Frequency

7.2.5. Analysis by Route of Administration

7.2.6. Analysis by Target Indication

7.2.7. Analysis by Type of Therapy

7.2.8. Analysis by Drug Designation

7.3. Gene and Cell Therapy-based Back of the Eye Disorders Related Drugs Landscape

7.3.1. Analysis by Stage of Development

7.3.2. Analysis by Dosing Frequency

7.3.3. Analysis by Target Indication

7.3.4. Analysis by Route of Administration

7.3.5. Analysis by Type of Therapy

7.4. Small Molecule-based Back of the Eye Disorders Related Drugs Landscape

7.4.1. Analysis by Stage of Development

7.4.2. Analysis by Dosing Frequency

7.4.3. Analysis by Target Indication

7.4.4. Analysis by Route of Administration

7.4.5. Analysis by Type of Therapy

7.5. Antibody-based Back of the Eye Disorders Related Drugs Landscape

7.5.1. Analysis by Stage of Development

7.5.2. Analysis by Dosing Frequency

7.5.3. Analysis by Target Indication

7.5.4. Analysis by Route of Administration

7.5.5. Analysis by Type of Therapy

7.6. Protein-based Back of the Eye Disorders Related Drugs Landscape

7.6.1. Analysis by Stage of Development

7.6.2. Analysis by Dosing Frequency

7.6.3. Analysis by Target Indication

7.6.4. Analysis by Route of Administration

7.6.5. Analysis by Type of Therapy

7.7. Peptide-based Back of the Eye Disorders Related Drugs Landscape

7.7.1. Analysis by Stage of Development

7.7.2. Analysis by Dosing Frequency

7.7.3. Analysis by Target Indication

7.7.4. Analysis by Route of Administration

7.7.5. Analysis by Type of Therapy

7.8. Back of the Eye Disorders Market: Developers Landscape

7.8.1. Analysis by Year of Establishment

7.8.2. Analysis by Company Size

7.8.3. Analysis by Location of Headquarters

7.8.4. Analysis by Company Size and Location of Headquarters

7.8.5. Most Active Players: Analysis by Number of Drugs

+ 8. BACK OF THE EYE DISORDERS MARKET: COMPANY COMPETITIVENESS ANALYSIS

8.1. Methodology and Key Parameters

8.2. Scoring Criteria

8.3. Overview of Peer Groups

8.3.1. Company Competitiveness Analysis: Developers based in North America (Peer Group I)

8.3.2. Company Competitiveness Analysis: Developers based in Europe (Peer Group II)

8.3.3. Company Competitiveness Analysis: Developers based in Asia-Pacific and Rest of the World (Peer Group III)

+ 9. COMPANY PROFILES: BACK OF THE EYE DISORDERS DRUG DEVELOPERS

9.1. Chapter Overview

9.2. AbbVie*

9.2.1. Company Overview

9.2.2. Management Team

9.2.3. Back of the Eye Drugs Portfolio

9.2.4. Key Initiatives

* Similar details are presented for other companies mentioned below (based on information in the public domain)

9.3. Astellas Pharma

9.4. Bausch + Lomb

9.5. Chiesi

9.6. Genentech

9.7. Novartis

9.8. Otsuka Pharmaceutical

9.9. Regeneron Pharmaceuticals

9.10. Roche

9.11. Sun Pharma

+ 10. MARKET IMPACT ANALYSIS

10.1. Chapter Overview

10.2. Market Drivers

10.3. Market Restraints

10.4. Market Opportunities

10.5. Market Challenges

+ 11. GLOBAL BACK OF THE EYE DISORDERS MARKET

11.1. Key Assumptions and Methodology

11.2. Global Back of The Eye Disorders Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

11.2.1. Scenario Analysis

11.2.1.1. Conservative Scenario

11.2.1.2. Optimistic Scenario

11.3. Key Market Segmentations

+ 12. BACK OF THE EYE DISORDERS MARKET, BY SCALE OF OPERATION

12.1. Key Assumptions and Methodology

12.2. Back of The Eye Disorders Market: Distribution by Scale of Operation

12.2.1. Back of The Eye Disorders Market at Clinical Scale, Forecasted Estimates (Till 2035)

12.2.2. Back of The Eye Disorders Market at Commercial Scale, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

+ 13. BACK OF THE EYE DISORDERS MARKET, BY TYPE OF MOLECULE

13.1. Key Assumptions and Methodology

13.2. Back of The Eye Disorders Market: Distribution by Type of Molecule

13.2.1. Back of The Eye Disorders Market for Biologics, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

13.2.2. Back of The Eye Disorders Market for Small Molecules, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

+ 14. BACK OF THE EYE DISORDERS MARKET, BY TARGET INDICATION

14.1. Key Assumptions and Methodology

14.2. Back of The Eye Disorders Market: Distribution by Target Indication

14.2.1. Back of The Eye Disorders Market for Diabetic Macular Edema, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

14.2.2. Back of The Eye Disorders Market for Neovascular (Wet) Age-Related Macular Degeneration, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

14.2.3. Back of The Eye Disorders Market for Diabetic Retinopathy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

14.2.4. Back of The Eye Disorders Market for Glaucoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

14.2.5. Back of The Eye Disorders Market for Geographic Atrophy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

14.2.6. Back of The Eye Disorders Market for Uveal Melanoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

14.2.7. Back of The Eye Disorders Market for Retinal Vein Occlusion, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

14.2.8. Back of The Eye Disorders Market for Uveitic Macular Edema, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

14.2.9. Back of The Eye Disorders Market for Choroidal Neovascularization, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

14.2.10. Back of The Eye Disorders Market for Biallelic RPE65 mutation-associated Retinal Dystrophy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

14.2.11. Back of The Eye Disorders Market for Retinopathy of Prematurity, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

14.2.12. Back of The Eye Disorders Market for Leber's Hereditary Optic Neuropathy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

+ 15. BACK OF THE EYE DISORDERS MARKET, BY GEOGRAPHICAL REGIONS

15.1. Key Assumptions and Methodology

15.2. Back of The Eye Disorders Market: Distribution by Geographical Regions

15.2.1. Back of The Eye Disorders Market in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.1.1. Back of The Eye Disorders Market in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.1.2. Back of The Eye Disorders Market in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.2. Back of The Eye Disorders Market in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.2.1. Back of The Eye Disorders Market in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.2.2. Back of The Eye Disorders Market in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.2.3. Back of The Eye Disorders Market in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.2.4. Back of The Eye Disorders Market in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.2.5. Back of The Eye Disorders Market in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.2.6. Back of The Eye Disorders Market in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.3. Back of The Eye Disorders Market in Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.3.1. Back of The Eye Disorders Market in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.3.2. Back of The Eye Disorders Market in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.3.3. Back of The Eye Disorders Market in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.3.4. Back of The Eye Disorders Market in South Korea, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.3.5. Back of The Eye Disorders Market in Australia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.3.6. Back of The Eye Disorders Market in Rest of Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.4. Back of The Eye Disorders Market in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.4.1. Back of The Eye Disorders Market in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.4.2. Back of The Eye Disorders Market in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.4.3. Back of The Eye Disorders Market in Rest of Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.5. Back of The Eye Disorders Market in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.5.1. Back of The Eye Disorders Market in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.5.2. Back of The Eye Disorders Market in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

15.2.5.3. Back of The Eye Disorders Market in Rest of Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

+ 16. BACK OF THE EYE DISORDERS MARKET: NORTH AMERICA

16.1. Back of The Eye Disorders Market in North America: Distribution by Scale of Operation

16.1.1. Back of The Eye Disorders Market in North America at Clinical Scale, Forecasted Estimates (till 2035)

16.1.2. Back of The Eye Disorders Market in North America at Commercial Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

16.2. Back of The Eye Disorders Market in North America: Distribution by Type of Molecule

16.2.1. Back of The Eye Disorders Market in North America for Biologics, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

16.2.2. Back of The Eye Disorders Market in North America for Small Molecules, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

16.3. Back of The Eye Disorders Market in North America: Distribution by Target Indication

16.3.1. Back of The Eye Disorders Market in North America for Diabetic Macular Edema, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

16.3.2. Back of The Eye Disorders Market in North America for Neovascular (Wet) Age-Related Macular Degeneration, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

16.3.3. Back of The Eye Disorders Market in North America for Diabetic Retinopathy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

16.3.4. Back of The Eye Disorders Market in North America for Glaucoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

16.3.5. Back of The Eye Disorders Market in North America for Geographic Atrophy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

16.3.6. Back of The Eye Disorders Market in North America for Uveal Melanoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

16.3.7. Back of The Eye Disorders Market in North America for Retinal Vein Occlusion, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

16.3.8. Back of The Eye Disorders Market in North America for Uveitic Macular Edema, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

16.3.9. Back of The Eye Disorders Market in North America for Choroidal Neovascularization, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

16.3.10. Back of The Eye Disorders Market in North America for Biallelic RPE65 mutation-associated Retinal Dystrophy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

16.3.11. Back of The Eye Disorders Market in North America for Retinopathy of Prematurity, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

16.3.12. Back of The Eye Disorders Market in North America for Leber's Hereditary Optic Neuropathy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

+ 17. BACK OF THE EYE DISORDERS MARKET: EUROPE

17.1. Back of The Eye Disorders Market in Europe: Distribution by Scale of Operation

17.1.1. Back of The Eye Disorders Market in Europe at Clinical Scale, Forecasted Estimates (till 2035)

17.1.2. Back of The Eye Disorders Market in Europe at Commercial Scale, Historical Trends (since 2017) and Forecasted Estimates (till 2035)

17.2. Back of The Eye Disorders Market in Europe: Distribution by Type of Molecule

17.2.1. Back of The Eye Disorders Market in Europe for Biologics, Historical Trends (since 2017) and Forecasted Estimates (till 2035)

17.2.2. Back of The Eye Disorders Market in Europe for Small Molecules, Historical Trends (since 2017) and Forecasted Estimates (till 2035)

17.3. Back of The Eye Disorders Market in Europe: Distribution by Target Indication

17.3.1. Back of The Eye Disorders Market in Europe for Diabetic Macular Edema, Historical Trends (Since 2017) and Forecasted Estimates (Till 2035)

17.3.2. Back of The Eye Disorders Market in Europe for Neovascular (Wet) Age-Related Macular Degeneration, Historical Trends (Since 2017) and Forecasted Estimates (Till 2035)

17.3.3. Back of The Eye Disorders Market in Europe for Diabetic Retinopathy, Historical Trends (Since 2017) and Forecasted Estimates (Till 2035)

17.3.4. Back of The Eye Disorders Market in Europe for Glaucoma, Historical Trends (Since 2017) and Forecasted Estimates (Till 2035)

17.3.5. Back of The Eye Disorders Market in Europe for Geographic Atrophy, Historical Trends (Since 2017) and Forecasted Estimates (Till 2035)

17.3.6. Back of The Eye Disorders Market in Europe for Uveal Melanoma, Historical Trends (Since 2017) and Forecasted Estimates (Till 2035)

17.3.7. Back of The Eye Disorders Market in Europe for Retinal Vein Occlusion, Historical Trends (Since 2017) and Forecasted Estimates (Till 2035)

17.3.8. Back of The Eye Disorders Market in Europe for Uveitic Macular Edema, Historical Trends (Since 2017) and Forecasted Estimates (Till 2035)

17.3.9. Back of The Eye Disorders Market in Europe for Choroidal Neovascularization, Historical Trends (Since 2017) and Forecasted Estimates (Till 2035)

17.3.10. Back of The Eye Disorders Market in Europe for Biallelic RPE65 mutation-associated Retinal Dystrophy, Historical Trends (Since 2017) and Forecasted Estimates (Till 2035)

17.3.11. Back of The Eye Disorders Market in Europe for Retinopathy of Prematurity, Historical Trends (Since 2017) and Forecasted Estimates (Till 2035)

17.3.12. Back of The Eye Disorders Market in Europe for Leber's Hereditary Optic Neuropathy, Historical Trends (Since 2017) and Forecasted Estimates (Till 2035)

+ 18. BACK OF THE EYE DISORDERS MARKET: ASIA-PACIFIC

18.1. Back of The Eye Disorders Market in Asia-Pacific: Distribution by Scale of Operation

18.1.1. Back of The Eye Disorders Market in Asia-Pacific at Clinical Scale, Forecasted Estimates (till 2035)

18.1.2. Back of The Eye Disorders Market in Asia-Pacific at Commercial Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

18.2. Back of The Eye Disorders Market in Asia-Pacific: Distribution by Type of Molecule

18.2.1. Back of The Eye Disorders Market in Asia-Pacific for Biologics, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

18.2.2. Back of The Eye Disorders Market in Asia-Pacific for Small Molecules, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

18.3. Back of The Eye Disorders Market in Asia-Pacific: Distribution by Target Indication

18.3.1. Back of The Eye Disorders Market in Asia-Pacific for Diabetic Macular Edema, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

18.3.2. Back of The Eye Disorders Market in Asia-Pacific for Neovascular (Wet) Age-Related Macular Degeneration, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

18.3.3. Back of The Eye Disorders Market in Asia-Pacific for Diabetic Retinopathy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

18.3.4. Back of The Eye Disorders Market in Asia-Pacific for Glaucoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

18.3.5. Back of The Eye Disorders Market in Asia-Pacific for Geographic Atrophy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

18.3.6. Back of The Eye Disorders Market in Asia-Pacific for Uveal Melanoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

18.3.7. Back of The Eye Disorders Market in Asia-Pacific for Retinal Vein Occlusion, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

18.3.8. Back of The Eye Disorders Market in Asia-Pacific for Uveitic Macular Edema, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

18.3.9. Back of The Eye Disorders Market in Asia-Pacific for Choroidal Neovascularization, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

18.3.10. Back of The Eye Disorders Market in Asia-Pacific for Biallelic RPE65 mutation-associated Retinal Dystrophy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

18.3.11. Back of The Eye Disorders Market in Asia-Pacific for Retinopathy of Prematurity, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

18.3.12. Back of The Eye Disorders Market in Asia-Pacific for Leber's Hereditary Optic Neuropathy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

+ 19. BACK OF THE EYE DISORDERS MARKET: MIDDLE EAST AND NORTH AFRICA

19.1. Back of The Eye Disorders Market in Middle East and North Africa: Distribution by Scale of Operation

19.1.1. Back of The Eye Disorders Market in Middle East and North Africa at Clinical Scale, Forecasted Estimates (till 2035)

19.1.2. Back of The Eye Disorders Market in Middle East and North Africa at Commercial Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

19.2. Back of The Eye Disorders Market in Middle East and North Africa: Distribution by Type of Molecule

19.2.1. Back of The Eye Disorders Market in Middle East and North Africa for Biologics, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

19.2.2. Back of The Eye Disorders Market in Middle East and North Africa for Small Molecules, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

19.3. Back of The Eye Disorders Market in Middle East and North Africa: Distribution by Target Indication

19.3.1. Back of The Eye Disorders Market in Middle East and North Africa for Diabetic Macular Edema, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

19.3.2. Back of The Eye Disorders Market in Middle East and North Africa for Neovascular (Wet) Age-Related Macular Degeneration, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

19.3.3. Back of The Eye Disorders Market in Middle East and North Africa for Diabetic Retinopathy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

19.3.4. Back of The Eye Disorders Market in Middle East and North Africa for Glaucoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

19.3.5. Back of The Eye Disorders Market in Middle East and North Africa for Geographic Atrophy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

19.3.6. Back of The Eye Disorders Market in Middle East and North Africa for Uveal Melanoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

19.3.7. Back of The Eye Disorders Market in Middle East and North Africa for Retinal Vein Occlusion, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

19.3.8. Back of The Eye Disorders Market in Middle East and North Africa for Uveitic Macular Edema, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

19.3.9. Back of The Eye Disorders Market in Middle East and North Africa for Choroidal Neovascularization, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

19.3.10. Back of The Eye Disorders Market in Middle East and North Africa for Biallelic RPE65 mutation-associated Retinal Dystrophy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

19.3.11. Back of The Eye Disorders Market in Middle East and North Africa for Retinopathy of Prematurity, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

19.3.12. Back of The Eye Disorders Market in Middle East and North Africa for Leber's Hereditary Optic Neuropathy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

+ 20. BACK OF THE EYE DISORDERS MARKET: LATIN AMERICA

20.1. Back of The Eye Disorders Market in Latin America: Distribution by Scale of Operation

20.1.1. Back of The Eye Disorders Market in Latin America at Clinical Scale, Forecasted Estimates (till 2035)

20.1.2. Back of The Eye Disorders Market in Latin America at Commercial Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

20.2. Back of The Eye Disorders Market in Latin America: Distribution by Type of Molecule

20.2.1. Back of The Eye Disorders Market in Latin America for Biologics, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

20.2.2. Back of The Eye Disorders Market in Latin America for Small Molecules, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

20.3. Back of The Eye Disorders Market in Latin America: Distribution by Target Indication

20.3.1. Back of The Eye Disorders Market in Latin America for Diabetic Macular Edema, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

20.3.2. Back of The Eye Disorders Market in Latin America for Neovascular (Wet) Age-Related Macular Degeneration, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

20.3.3. Back of The Eye Disorders Market in Latin America for Diabetic Retinopathy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

20.3.4. Back of The Eye Disorders Market in Latin America for Glaucoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

20.3.5. Back of The Eye Disorders Market in Latin America for Geographic Atrophy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

20.3.6. Back of The Eye Disorders Market in Latin America for Uveal Melanoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

20.3.7. Back of The Eye Disorders Market in Latin America for Retinal Vein Occlusion, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

20.3.8. Back of The Eye Disorders Market in Latin America for Uveitic Macular Edema, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

20.3.9. Back of The Eye Disorders Market in Latin America for Choroidal Neovascularization, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

20.3.10. Back of The Eye Disorders Market in Latin America for Biallelic RPE65 mutation-associated Retinal Dystrophy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

20.3.11. Back of The Eye Disorders Market in Latin America for Retinopathy of Prematurity, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

20.3.12. Back of The Eye Disorders Market in Latin America for Leber's Hereditary Optic Neuropathy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

**Detailed information on Chapters 16 to 20 is available in the Excel Data Packs shared along with the report**

+ 21. BACK OF THE EYE DISORDERS MARKET, BY KEY PLAYERS

+ 22. BACK OF THE EYE DISORDERS MARKET, SALES FORECAST OF COMMERCIALIZED DRUGS

22.1. Back of the Eye Disorders Market: Commercialized Drug Sales Forecast

22.1.1. ALPHAGAN® P / COMBIGAN® Franchise

22.1.2. AZARGA®

22.1.3. Beovu® (brolucizumab) / RTH258

22.1.4. Duotrav™

22.1.5. Eylea HD® (aflibercept)

22.1.6. Eylea® (aflibercept)

22.1.7. IZERVAY™

22.1.8. KIMMTRAK® (tebentafusp-tebn)

22.1.9. Latanoprost / DE-130A / (Catioprost) / Catiolanze®

22.1.10. Lucentis® / Ranibizumab

22.1.11. Lumigan/Ganfort

22.1.12. Lumitin® (Conbercept Ophthalmic Solution) / KH902

22.1.13. LUXTURNA® (voretigene neparvovec-rzyl)

22.1.14. NCX 470 / OT-301 / K-911

22.1.15. Omidenepag / Isopropyl / OMLONTI® / Eybelis / DE-117

22.1.16. ONS-5010 / LYTENAVA™

22.1.17. Raxone® / Idebenone

22.1.18. Rhopressa® + ROCKLATAN™

22.1.19. Sepetaprost / DE-126 / SETANEO® Ophthalmic Solution

22.1.20. Simbrinza®

22.1.21. SYFOVRE® (pegcetacoplan injection)

22.1.22. Tafluprost / Timolol Maleate / TAPCOM Combination Ophthalmic Solution

22.1.23. Travatan Z® / Travoprost

22.1.24. Vabysmo (faricimab-sova, RG7716)

22.1.25. VYZULTA®

22.1.26. XIPERE® / ARCATUS® / ARVN001

+ 23. CONCLUDING REMARKS

+ 24. EXECUTIVE INSIGHTS

24.1. Chapter Overview

24.2. Company A

24.2.1 Interview Transcript: Former Chief Executive Officer

24.3. Company B

24.3.1. Interview Transcript: Former Senior Vice President

24.4. Company C

24.4.1. Interview Transcript: Former President and Chief Executive Officer

24.5. Company D

24.5.1. Interview Transcript: Postdoctoral Researcher

24.6. Company E

24.6.1. Interview Transcript: Assistant Professor

24.7. Company F

24.7.1. Interview Transcript: Associate Professor & Senior Consultant

+ 25. APPENDIX 1: TABULATED DATA

+ 26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

+ List of Figures

Figure 2.1 Research Methodology: Project Methodology

Figure 2.2 Research Methodology: Data Sources for Secondary Research

Figure 2.3 Research Methodology: Robust Quality Control

Figure 3.1 Market Dynamics: Forecast Methodology

Figure 3.2 Market Dynamics: Market Assessment Framework

Figure 4.1 Lessons Learnt from Past Recessions

Figure 5.1 Executive Summary: Market Landscape

Figure 5.2 Executive Summary: Market Sizing and Opportunity Analysis

Figure 6.1 Prominent Back of the Eye Disorders

Figure 6.2 Factors Contributing to Back of the Eye Disorders

Figure 6.3 Sign and Symptoms of Back of the Eye Disorders

Figure 7.1 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Stage of Development

Figure 7.2 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Type of Molecule

Figure 7.3 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Mechanism of Action

Figure 7.4 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Dosing Frequency

Figure 7.5 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Route of Administration

Figure 7.6 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Target Indication

Figure 7.7 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Type of Therapy

Figure 7.8 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Drug Designation

Figure 7.9 Gene and Cell Therapy-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Stage of Development

Figure 7.10 Gene and Cell Therapy-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Dosing Frequency

Figure 7.11 Gene and Cell Therapy-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Target Indication

Figure 7.12 Gene and Cell Therapy-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Route of Administration

Figure 7.13 Gene and Cell Therapy-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Type of Therapy

Figure 7.14 Small Molecule-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Stage of Development

Figure 7.15 Small Molecule-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Dosing Frequency

Figure 7.16 Small Molecule-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Target Indication

Figure 7.17 Small Molecule-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Route of Administration

Figure 7.18 Small Molecule-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Type of Therapy

Figure 7.19 Antibody-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Stage of Development

Figure 7.20 Antibody-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Dosing Frequency

Figure 7.21 Antibody-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Target Indication

Figure 7.22 Antibody-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Route of Administration

Figure 7.23 Antibody-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Type of Therapy

Figure 7.24 Protein-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Stage of Development

Figure 7.25 Protein-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Dosing Frequency

Figure 7.26 Protein-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Target Indication

Figure 7.27 Protein-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Route of Administration

Figure 7.28 Protein-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Type of Therapy

Figure 7.29 Peptide-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Stage of Development

Figure 7.30 Peptide-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Dosing Frequency

Figure 7.31 Peptide-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Target Indication

Figure 7.32 Peptide-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Route of Administration

Figure 7.33 Peptide-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Type of Therapy

Figure 7.34 Back of the Eye Disorders (Developers Landscape): Distribution by Year of Establishment

Figure 7.35 Back of the Eye Disorders (Developers Landscape): Distribution by Company Size

Figure 7.36 Back of the Eye Disorders (Developers Landscape): Distribution by Location of Headquarters

Figure 7.37 Back of the Eye Disorders (Developers Landscape): Distribution by Company Size and Location of Headquarters

Figure 7.38 Most Active Players: Distribution by Number of Drugs

Figure 8.1 Back of the Eye Disorders Drug Developers based in North America: Distribution by Company Size

Figure 8.2 Back of the Eye Disorders Drug Developers based in North America: Distribution by Stage of Development

Figure 8.3 Back of the Eye Disorders Drug Developers based in North America: Distribution by Type of Molecule

Figure 8.4 Competitive Analysis of Developers based in North America

Figure 8.5 Back of the Eye Disorders Drug Developers based in Europe: Distribution by Company Size

Figure 8.6 Back of the Eye Disorders Drug Developers based in Europe: Distribution by Type of Molecule

Figure 8.7 Competitive Analysis of Developers based in Europe

Figure 8.8 Back of the Eye Disorders Drug Developers based in Asia-Pacific and Rest of the World: Distribution by Company Size

Figure 8.9 Back of the Eye Disorders Drug Developers based in Asia-Pacific and Rest of the World: Distribution by Stage of Development

Figure 8.10 Back of the Eye Disorders Drug Developers based in Asia-Pacific and Rest of the World: Distribution by Type of Molecule

Figure 8.11 Competitive Analysis of Developers based in Asia-Pacific and Rest of the World

Figure 10.1 Drivers v/s Restraints

Figure 10.2 Opportunities v/s Challenges

Figure 11.1 Back of the Eye Disorders Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 11.2 Back of the Eye Disorders Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)

Figure 11.3 Back of the Eye Disorders Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)

Figure 12.1 Back of The Eye Disorders Market: Distribution by Scale of Operation

Figure 12.2 Back of The Eye Disorders Market at Clinical Scale, Forecasted Estimates (Till 2035) (USD Billion)

Figure 12.3 Back of The Eye Disorders Market at Commercial Scale, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 13.1 Back of The Eye Disorders Market: Distribution by Type of Molecule

Figure 13.2 Back of The Eye Disorders Market for Biologics, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 13.3 Back of The Eye Disorders Market for Small Molecules, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 14.1 Back of The Eye Disorders Market: Distribution by Target Indication

Figure 14.2 Back of The Eye Disorders Market for Diabetic Macular Edema, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 14.3 Back of The Eye Disorders Market for Neovascular (Wet) Age-Related Macular Degeneration, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 14.4 Back of The Eye Disorders Market for Diabetic Retinopathy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 14.5 Back of The Eye Disorders Market for Glaucoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 14.6 Back of The Eye Disorders Market for Geographic Atrophy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USDBillion)

Figure 14.7 Back of The Eye Disorders Market for Uveal Melanoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 14.8 Back of The Eye Disorders Market for Retinal Vein Occlusion, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 14.9 Back of The Eye Disorders Market for Uveitic Macular Edema, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 14.10 Back of The Eye Disorders Market for Choroidal Neovascularization, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 14.11 Back of The Eye Disorders Market for Biallelic RPE65 mutation-associated Retinal Dystrophy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 14.12 Back of The Eye Disorders Market for Retinopathy of Prematurity, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 14.13 Back of The Eye Disorders Market for Leber's Hereditary Optic Neuropathy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.1 Back of the Eye Disorders Market: Distribution by Geographical Regions

Figure 15.2 Back of the Eye Disorders Market in North America: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.3 Back of the Eye Disorders Market in the US: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.4 Back of the Eye Disorders Market in Canada: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion))

Figure 15.5 Back of the Eye Disorders Market in Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.6 Back of the Eye Disorders Market in Germany: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.7 Back of the Eye Disorders Market in the UK: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.8 Back of the Eye Disorders Market in France: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.9 Back of the Eye Disorders Market in Italy: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.10 Back of the Eye Disorders Market in Spain: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.11 Back of the Eye Disorders Market in Rest of Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.12 Back of The Eye Disorders Market in Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.13 Back of The Eye Disorders Market in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.14 Back of The Eye Disorders Market in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.15 Back of The Eye Disorders Market in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.16 Back of The Eye Disorders Market in South Korea, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.17 Back of The Eye Disorders Market in Australia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.18 Back of The Eye Disorders Market in Rest of Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.19 Back of The Eye Disorders Market in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.20 Back of The Eye Disorders Market in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.21 Back of The Eye Disorders Market in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.22 Back of The Eye Disorders Market in Rest of Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.23 Back of The Eye Disorders Market in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.24 Back of The Eye Disorders Market in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.25 Back of The Eye Disorders Market in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 15.26 Back of The Eye Disorders Market in Rest of Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 21.1 Back of the Eye Disorders Market: Distribution by Distribution by Key Players, (based on revenues generated)

Figure 21.2 Back of the Eye Disorders Market: Distribution by Distribution by Key Players, 2035 (based on forecasted revenues)

Figure 22.1 Back of the Eye Disorders Market for ALPHAGAN® P / COMBIGAN® Franchise, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.2 Back of the Eye Disorders Market for AZARGA®, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.3 Back of the Eye Disorders Market for Beovu® (brolucizumab) / RTH258, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.4 Back of the Eye Disorders Market for Duotrav™, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.5 Back of the Eye Disorders Market for Eylea HD® (aflibercept), Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.6 Back of the Eye Disorders Market for Eylea® (aflibercept), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.7 Back of the Eye Disorders Market for IZERVAY™, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.8 Back of the Eye Disorders Market for KIMMTRAK® (tebentafusp-tebn), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.9 Back of the Eye Disorders Market for Latanoprost / DE-130A / (Catioprost) / Catiolanze®, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.10 Back of the Eye Disorders Market for Lucentis® / Ranibizumab, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.11 Back of the Eye Disorders Market for Lumigan/Ganfort, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.12 Back of the Eye Disorders Market for Lumitin® (Conbercept Ophthalmic Solution) / KH902, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.13 Back of the Eye Disorders Market for LUXTURNA® (voretigene neparvovec-rzyl), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.14 Back of the Eye Disorders Market for NCX 470 / OT-301 / K-911, Forecasted Estimates (Till 2035) (USD Million)

Figure 22.15 Back of the Eye Disorders Market for Omidenepag / Isopropyl / OMLONTI® / Eybelis / DE-117, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.16 Back of the Eye Disorders Market for ONS-5010 / LYTENAVA™, Historical Trends (Since 2025) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.17 Back of the Eye Disorders Market for Raxone® / Idebenone, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.18 Back of the Eye Disorders Market for Rhopressa® + ROCKLATAN™, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.19 Back of the Eye Disorders Market for Sepetaprost / DE-126 / SETANEO® Ophthalmic Solution, Historical Trends (Since 2025) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.20 Back of the Eye Disorders Market for Simbrinza®, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.21 Back of the Eye Disorders Market for SYFOVRE® (pegcetacoplan injection), Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.22 Back of the Eye Disorders Market for Tafluprost / Timolol Maleate / TAPCOM Combination Ophthalmic Solution, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.23 Back of the Eye Disorders Market for Travatan Z® / Travoprost, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.24 Back of the Eye Disorders Market for Vabysmo (faricimab-sova, RG7716), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.25 Back of the Eye Disorders Market for VYZULTA®, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.26 Back of the Eye Disorders Market for XIPERE® / ARCATUS® / ARVN001, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

+ List of Tables

Table 7.1 Back of the Eye Disorders Market: List of Drugs

Table 7.2 Back of the Eye Disorders Market: List of Drug Developers

Table 11.1 Back of the Eye Disorders Market: List of Forecasted Drugs

Table 25.1 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Stage of Development

Table 25.2 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Type of Molecule

Table 25.3 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Mechanism of Action

Table 25.4 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Dosing Frequency

Table 25.5 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Route of Administration

Table 25.6 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Target Indication

Table 25.7 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Type of Therapy

Table 25.8 Back of the Eye Disorders Market: Drugs Landscape: Distribution by Drug Designation

Table 25.9 Gene and Cell Therapy-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Stage of Development

Table 25.10 Gene and Cell Therapy-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Dosing Frequency

Table 25.11 Gene and Cell Therapy-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Target Indication

Table 25.12 Gene and Cell Therapy-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Route of Administration

Table 25.13 Gene and Cell Therapy-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Type of Therapy

Table 25.14 Small Molecule-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Stage of Development

Table 25.15 Small Molecule-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Dosing Frequency

Table 25.16 Small Molecule-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Target Indication

Table 25.17 Small Molecule-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Route of Administration

Table 25.18 Small Molecule-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Type of Therapy

Table 25.19 Antibody-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Stage of Development

Table 25.20 Antibody-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Dosing Frequency

Table 25.21 Antibody-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Target Indication

Table 25.22 Antibody-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Route of Administration

Table 25.23 Antibody-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Type of Therapy

Table 25.24 Protein-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Stage of Development

Table 25.25 Protein-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Dosing Frequency

Table 25.26 Protein-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Target Indication

Table 25.27 Protein-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Route of Administration

Table 25.28 Protein-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Type of Therapy

Table 25.29 Peptide-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Stage of Development

Table 25.30 Peptide-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Dosing Frequency

Table 25.31 Peptide-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Target Indication

Table 25.32 Peptide-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Route of Administration

Table 25.33 Peptide-based Back of the Eye Disorders Related Drugs Landscape: Distribution by Type of Therapy

Table 25.34 Back of the Eye Disorders (Developers Landscape): Distribution by Year of Establishment

Table 25.35 Back of the Eye Disorders (Developers Landscape): Distribution by Company Size

Table 25.36 Back of the Eye Disorders (Developers Landscape): Distribution by Location of Headquarters

Table 25.37 Back of the Eye Disorders (Developers Landscape): Distribution by Company Size and Location of Headquarters

Table 25.38 Most Active Players: Distribution by Number of Drugs

Table 25.39 Back of the Eye Disorders Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Table 25.40 Back of the Eye Disorders Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)

Table 25.41 Back of the Eye Disorders Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)

Table 25.42 Back of The Eye Disorders Market: Distribution by Scale of Operation

Table 25.43 Back of The Eye Disorders Market at Clinical Scale, Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.44 Back of The Eye Disorders Market at Commercial Scale, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.45 Back of The Eye Disorders Market: Distribution by Type of Molecule

Table 25.46 Back of The Eye Disorders Market for Biologics, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.47 Back of The Eye Disorders Market for Small Molecules, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.48 Back of The Eye Disorders Market: Distribution by Target Indication

Table 25.49 Back of The Eye Disorders Market for Diabetic Macular Edema, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.50 Back of The Eye Disorders Market for Neovascular (Wet) Age-Related Macular Degeneration, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.51 Back of The Eye Disorders Market for Diabetic Retinopathy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.52 Back of The Eye Disorders Market for Glaucoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.53 Back of The Eye Disorders Market for Geographic Atrophy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USDBillion)

Table 25.54 Back of The Eye Disorders Market for Uveal Melanoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.55 Back of The Eye Disorders Market for Retinal Vein Occlusion, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.56 Back of The Eye Disorders Market for Uveitic Macular Edema, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.57 Back of The Eye Disorders Market for Choroidal Neovascularization, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.58 Back of The Eye Disorders Market for Biallelic RPE65 mutation-associated Retinal Dystrophy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.59 Back of The Eye Disorders Market for Retinopathy of Prematurity, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.60 Back of The Eye Disorders Market for Leber's Hereditary Optic Neuropathy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.61 Back of the Eye Disorders Market: Distribution by Geographical Regions

Table 25.62 Back of the Eye Disorders Market in North America: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.63 Back of the Eye Disorders Market in the US: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.64 Back of the Eye Disorders Market in Canada: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion))

Table 25.65 Back of the Eye Disorders Market in Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.66 Back of the Eye Disorders Market in Germany: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.67 Back of the Eye Disorders Market in the UK: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.68 Back of the Eye Disorders Market in France: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.69 Back of the Eye Disorders Market in Italy: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.70 Back of the Eye Disorders Market in Spain: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.71 Back of the Eye Disorders Market in Rest of Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.72 Back of The Eye Disorders Market in Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.73 Back of The Eye Disorders Market in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.74 Back of The Eye Disorders Market in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.75 Back of The Eye Disorders Market in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.76 Back of The Eye Disorders Market in South Korea, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.77 Back of The Eye Disorders Market in Australia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.78 Back of The Eye Disorders Market in Rest of Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.79 Back of The Eye Disorders Market in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.80 Back of The Eye Disorders Market in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.81 Back of The Eye Disorders Market in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.82 Back of The Eye Disorders Market in Rest of Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.83 Back of The Eye Disorders Market in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.84 Back of The Eye Disorders Market in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.85 Back of The Eye Disorders Market in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.86 Back of The Eye Disorders Market in Rest of Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Table 25.87 Back of the Eye Disorders Market: Distribution by Distribution by Key Players, 2026 (based on revenues generated)

Table 25.88 Back of the Eye Disorders Market: Distribution by Distribution by Key Players, 2035 (based on forecasted revenues)

Table 25.89 Back of the Eye Disorders Market for ALPHAGAN® P / COMBIGAN® Franchise, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.90 Back of the Eye Disorders Market for AZARGA®, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.91 Back of the Eye Disorders Market for Beovu® (brolucizumab) / RTH258, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.92 Back of the Eye Disorders Market for Duotrav™, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.93 Back of the Eye Disorders Market for Eylea HD® (aflibercept), Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.94 Back of the Eye Disorders Market for Eylea® (aflibercept), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.95 Back of the Eye Disorders Market for IZERVAY™, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.96 Back of the Eye Disorders Market for KIMMTRAK® (tebentafusp-tebn), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.97 Back of the Eye Disorders Market for Latanoprost / DE-130A / (Catioprost) / Catiolanze®, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.98 Back of the Eye Disorders Market for Lucentis® / Ranibizumab, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.99 Back of the Eye Disorders Market for Lumigan/Ganfort, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.100 Back of the Eye Disorders Market for Lumitin® (Conbercept Ophthalmic Solution) / KH902, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.101 Back of the Eye Disorders Market for LUXTURNA® (voretigene neparvovec-rzyl), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.102 Back of the Eye Disorders Market for NCX 470 / OT-301 / K-911, Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.103 Back of the Eye Disorders Market for Omidenepag / Isopropyl / OMLONTI® / Eybelis / DE-117, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.104 Back of the Eye Disorders Market for ONS-5010 / LYTENAVA™, Historical Trends (Since 2025) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.105 Back of the Eye Disorders Market for Raxone® / Idebenone, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.106 Back of the Eye Disorders Market for Rhopressa® + ROCKLATAN™, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.107 Back of the Eye Disorders Market for Sepetaprost / DE-126 / SETANEO® Ophthalmic Solution, Historical Trends (Since 2025) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.108 Back of the Eye Disorders Market for Simbrinza®, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.109 Back of the Eye Disorders Market for SYFOVRE® (pegcetacoplan injection), Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.110 Back of the Eye Disorders Market for Tafluprost / Timolol Maleate / TAPCOM Combination Ophthalmic Solution, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.111 Back of the Eye Disorders Market for Travatan Z® / Travoprost, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.112 Back of the Eye Disorders Market for Vabysmo (faricimab-sova, RG7716), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.113 Back of the Eye Disorders Market for VYZULTA®, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Table 25.114 Back of the Eye Disorders Market for XIPERE® / ARCATUS® / ARVN001, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Million)

Back of the Eye Disorders Market